CD26: an expanding role in immune regulation and cancer.
In this review, we highlight major aspects of the biology of CD26, a dipeptidyl peptidase IV (DPPIV)-containing surface glycoprotein with multiple functions. In particular, we discuss findings demonstrating that CD26/DPPIV has an essential role in immune regulation as a T cell activation molecule and a regulator of chemokine function. We also review recent studies that identify key cellular molecules that physically associate with CD26 and the potential consequences of their interaction, including those with clinically-related implications. Furthermore, we present work suggesting a role for CD26 in the pathogenesis and behavior of selected human cancers, both solid tumors and hematological malignancies. We present recent studies that investigate the potential role of CD26 as a molecular target for novel treatment modalities for T cell lymphoid malignancies and possibly other hematological malignancies, with work involving the use of anti-CD26 monoclonal antibody, CD26-transfected cells as well as soluble CD26 molecules.
Dang
N H
NH
Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Box 429, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. nhdang@mail.mdanderson.org
Morimoto
C
C
D000818:Animals; D018819:Dipeptidyl Peptidase 4 / Q000502:physiology*; D006801:Humans; D007107:Immune System / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology
D018819:Dipeptidyl Peptidase 4